Published in J Eur Acad Dermatol Venereol on August 29, 2014
Dermographism in the Oral Cavity. Am J Case Rep (2016) 0.75
Brain-derived neurotrophic factor is increased in serum levels of patients with symptomatic dermographism. Postepy Dermatol Alergol (2017) 0.75
Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature (2000) 5.86
EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy (2009) 4.10
EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy (2009) 3.86
CENP-C, an autoantigen in scleroderma, is a component of the human inner kinetochore plate. Cell (1992) 3.70
The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy (2014) 3.10
A comprehensive guide for the recognition and classification of distinct stages of hair follicle morphogenesis. J Invest Dermatol (1999) 2.92
Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy (2010) 2.34
Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis. Pediatr Res (1993) 2.22
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Home versus hospital deliveries: follow up study of matched pairs for procedures and outcome. Zurich Study Team. BMJ (1996) 2.10
Mast cells as sentinels of innate immunity. Curr Opin Immunol (1999) 1.85
Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GA2LEN project. Allergy (2006) 1.84
Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature (1997) 1.78
EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria. Allergy (2009) 1.65
Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: a placebo-controlled trial. Dermatology (2006) 1.65
Night-time sedating H1 -antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial. Br J Dermatol (2014) 1.60
Human skin mast cells: their dispersion, purification, and secretory characterization. J Immunol (1987) 1.58
Molecular cloning, chromosome mapping and characterization of UBQLN3 a testis-specific gene that contains an ubiquitin-like domain. Gene (2000) 1.57
How to assess disease activity in patients with chronic urticaria? Allergy (2008) 1.55
EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy (2006) 1.55
Proceedings: The inhibitory effect of insulin on pinnal anaphylaxis in the mouse. Br J Pharmacol (1974) 1.54
Embolization of biologic glue during repair of aortic dissection. Ann Thorac Surg (1995) 1.52
How best to fight that nasty itch - from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol (2005) 1.51
Control of murine hair follicle regression (catagen) by TGF-beta1 in vivo. FASEB J (2000) 1.48
Characterization of histamine secretion from mechanically dispersed human lung mast cells: effects of anti-IgE, calcium ionophore A23187, compound 48/80, and basic polypeptides. J Immunol (1982) 1.45
Histamine release upon adenosine 5'-monophosphate (AMP) nasal provocation in allergic subjects. Thorax (1999) 1.43
A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc Natl Acad Sci U S A (2001) 1.43
Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy (2010) 1.42
Immunoglobulin E decapeptide-induced 5-hydroxytryptamine release from rat peritoneal mast cells. Comparison with corticotropin-(1-24)-peptide, polyarginine, polylysine and antigen. Biochem J (1981) 1.41
H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy (2002) 1.41
Fatal recurrent subarachnoid hemorrhage after complete endovascular aneurysm occlusion. AJNR Am J Neuroradiol (2006) 1.40
The definition and diagnostic testing of physical and cholinergic urticarias--EAACI/GA2LEN/EDF/UNEV consensus panel recommendations. Allergy (2009) 1.39
Adenosine inhibits and potentiates IgE-dependent histamine release from human lung mast cells by an A2-purinoceptor mediated mechanism. Biochem Pharmacol (1984) 1.38
Schnitzler's syndrome: diagnosis, treatment, and follow-up. Allergy (2013) 1.35
NMR solution structure of a complex of calmodulin with a binding peptide of the Ca2+ pump. Biochemistry (1999) 1.33
Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine. Clin Exp Allergy (1992) 1.32
Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. Genes Dev (1998) 1.31
Adenosine inhibits and potentiates IgE-dependent histamine release from human basophils by an A2-receptor mediated mechanism. Br J Pharmacol (1983) 1.29
p53 is essential for chemotherapy-induced hair loss. Cancer Res (2000) 1.29
EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy (2006) 1.28
Melanogenesis during the anagen-catagen-telogen transformation of the murine hair cycle. J Invest Dermatol (1994) 1.27
The inhibition by dexamethasone and disodium cromoglycate of anaphylactic bronchoconstriction in the rat. Br J Pharmacol (1972) 1.27
Human mast cell heterogeneity: histamine release from mast cells dispersed from skin, lung, adenoids, tonsils, and colon in response to IgE-dependent and nonimmunologic stimuli. J Allergy Clin Immunol (1988) 1.27
Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells. J Invest Dermatol (1994) 1.27
A simultaneous (15)N, (1)H- and (13)C, (1)H-HSQC with sensitivity enhancement and a heteronuclear gradient echo. J Biomol NMR (1995) 1.25
Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. Am Rev Respir Dis (1985) 1.25
Impaired mast cell development and innate immunity in Mac-1 (CD11b/CD18, CR3)-deficient mice. J Immunol (1998) 1.25
Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol (2006) 1.24
Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol. Br J Pharmacol (1987) 1.24
Early and late-phase bronchoconstriction after allergen challenge of nonanesthetized guinea pigs. I. The association of disordered airway physiology to leukocyte infiltration. Am Rev Respir Dis (1988) 1.24
Inhibition of histamine release from human lung in vitro by antihistamines and related drugs. Br J Pharmacol (1980) 1.23
Tumour necrosis factor alpha: a potential mediator of asthma. Clin Exp Allergy (1995) 1.21
Characterization of functional vanilloid receptors expressed by mast cells. Blood (1998) 1.21
p53 Involvement in the control of murine hair follicle regression. Am J Pathol (2001) 1.19
Immunohistochemical identification of mast cells in formaldehyde-fixed tissue using monoclonal antibodies specific for tryptase. J Pathol (1990) 1.17
Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy (2014) 1.16
Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction. J Appl Physiol (1985) (1989) 1.16
Heterogeneity of human mast cells based on cytokine content. J Immunol (1995) 1.15
Re-engineering the toilet for sustainable waste water management. Environ Sci Technol (2001) 1.14
Rupatadine in allergic rhinitis and chronic urticaria. Allergy (2008) 1.13
Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol (2010) 1.12
The relationship between cyclic AMP changes and histamine release from basophil-rich human leucocytes. Biochem Pharmacol (1983) 1.12
Human mast cells express stem cell factor. J Pathol (1998) 1.12
Antibacterial effects of cefroxadine, cephalexin and cephradine in a new in vitro pharmacokinetic model. J Antibiot (Tokyo) (1982) 1.11
Response of rat lung to humoral mediators of anaphylaxis and its modification by drugs and sensitization. Br J Pharmacol (1975) 1.10
Role of nasal interleukin-8 in neutrophil recruitment and activation in children with virus-induced asthma. Am J Respir Crit Care Med (1997) 1.10
Adenosine potentiates immunological histamine release from rat mast cells by a novel cyclic AMP-independent cell-surface action. Br J Pharmacol (1985) 1.10
Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy (2013) 1.09
IgE-dependent expression of mRNA for IL-4 and IL-5 in human lung mast cells. J Immunol (1995) 1.08
Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry (2008) 1.08
Release of mast-cell-derived mediators after endobronchial adenosine challenge in asthma. Am J Respir Crit Care Med (1995) 1.07
Studies on the receptor mediating cyclic AMP-independent enhancement by adenosine of IgE-dependent mediator release from rat mast cells. Br J Pharmacol (1986) 1.07
The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings. Allergy (2009) 1.07
Non-IgE-dependent bacteria-induced histamine release from human lung and tonsillar mast cells. Clin Allergy (1987) 1.06
Mast cell involvement in murine hair growth. Dev Biol (1994) 1.06
Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review. Allergy (2014) 1.05
Corticosteroid treatment reduces mast cell numbers in inflammatory bowel disease. Dig Dis Sci (1990) 1.04
The neurogenic vasodilator response to endothelin-1: a study in human skin in vivo. Exp Physiol (2000) 1.04
Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells. Oncogene (2007) 1.04
Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy (2008) 1.04
Role of eosinophil activation in the bronchial reactivity of allergic guinea pigs. Am J Respir Crit Care Med (1994) 1.03
Histamine is released in the wheal but not the flare following challenge of human skin in vivo: a microdialysis study. Clin Exp Allergy (1997) 1.02
9 alpha,11 beta-prostaglandin F2, a novel metabolite of prostaglandin D2 is a potent contractile agonist of human and guinea pig airways. J Clin Invest (1987) 1.02
Mast cells as initiators of immunity and host defense. Exp Dermatol (2001) 1.02
Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey. Eur J Clin Microbiol Infect Dis (2009) 1.01
The response of plasma histamine to bronchoprovocation with methacholine, adenosine 5'-monophosphate, and allergen in atopic nonasthmatic subjects. Am Rev Respir Dis (1990) 1.01
Leukocyte recruitment after local endobronchial allergen challenge in asthma. Relationship to procedure and to airway interleukin-8 release. Am J Respir Crit Care Med (1996) 1.01
Characterization of neuropeptide-induced histamine release from human dispersed skin mast cells. Br J Pharmacol (1988) 1.00
Effects of H1 antagonists on the cutaneous vascular response to histamine and bradykinin: a study using scanning laser Doppler imaging. Br J Dermatol (1998) 1.00
Matrix metalloproteinase-9: a novel biomarker for monitoring disease activity in patients with chronic urticaria patients? Allergy (2009) 1.00
Potential immunocompetence of proteolytic fragments produced by proteasomes before evolution of the vertebrate immune system. J Exp Med (1997) 1.00